Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

• Status: Terminated
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)

International study with sites in the Czech Republic and Poland

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: InterMune
• Treatments: Interferon-gamma; Interferons; Rituximab

Criteria

• Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy

• Patients who were on other therapy including CHOP or radiation

• Previous therapy must have concluded 30 days prior to enrollment

• Demonstrable CD20-positive tumor population in lymph nodes or bone marrow